CCP
ALXN

Corient Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Corient Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,997
Closed -$551K – 735
2021
Q2 		$551K Buy
2,997
+255
+9% +$43.8K 0.04% 336
2021
Q1 		$420K Buy
2,742
+378
+16% +$58.5K 0.04% 355
2020
Q4 		$369K Buy
2,364
+508
+27% +$65.3K 0.04% 333
2020
Q3 		$212K Sell
1,856
-150
-7% -$16.2K 0.02% 437
2020
Q2 		$225K Buy
+2,006
New +$213K 0.03% 407
2019
Q4 		– Sell
-8,401
Closed -$822K – 491
2019
Q3 		$822K Buy
+8,401
New +$947K 0.12% 187

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Corient Capital Partners's ALXN Position: Q3 2021 in Review

Corient Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,997 shares — an estimated $551K sold.

Corient Capital Partners first reported a position in ALXN in Q3 2019 and held it in 6 quarters. The position peaked at $822K in Q3 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Corient Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Corient Capital Partners sold 2,997 Alexion Pharmaceuticals shares in Q3 2021, an estimated $551K.
  • Corient Capital Partners first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 6 quarters.
  • Corient Capital Partners's Alexion Pharmaceuticals position peaked at $822K in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Corient Capital Partners's 13F filing for Q3 2021, filed 16 Nov 2021.